Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 8 Issue 8

Experimental Assessment of the Oncoprotective Properties of Low-Molecular Chitosan and its Effects on Cytostatic and Radiation Myelosuppression

AV Troitsky1*, TN Bystrova1, RA Knyazev1, NV Trifonova1, AA Rozhkov2, NA Mamontov2, KA Rozhkova2 and BA Zhigadlo2

1Federal Research Centre for Fundamental and Translational Medicine, Novosibirsk, Russia
2Innovative Health Technologies LLC, Novosibirsk, Russia

*Corresponding Author: AV Troitsky, Federal Research Centre for Fundamental and Translational Medicine, Novosibirsk, Russia.

Received: June 24, 2024; Published: July 31, 2024

Abstract

The effects of low-molecular chitosan were studied in experimental models of leukopenia in mice caused by cyclophosphamide and gamma radiation. The oncoprotective effect of low-molecular chitosan on the solid lymphosarcoma model of mice was studied. Low-molecular chitosan has been shown to have an oncoprotective effect and to effectively compensate for leukopenia caused by cytostatic and gamma radiation.

 Keywords: Chitosan; Cytostatic and Radiation Leukopenia; Cancer Protection

References

  1. Vermorken Jan B. “Cetuximab: Its unique place in head and neck cancer treatment”. Biologics Targets and Therapy 1 (2013): 77-90.
  2. Zhang J., et al. “Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials”. Saudi Medical Journal11 (2016): 1184-1190.
  3. Greenhalgh J., et al. “Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation”. Health Technology Assessment47 (2015): 1-134.
  4. Bouabdallah K., et al. “Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects”. Current Opinion Oncology 25 (2013): S1-12.
  5. Ambrosio AJ., et al. “Vintafolide (EC145) for the treatment of folate-receptor-alpha positive platinum-resistant ovarian cancer”. Expert Review of Clinical Pharmacology 4 (2014): 443-450.
  6. Zhang Y., et al. “Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China”. Cancer Research Clinical Oncology11 (2018): 2177-2186.
  7. Motta F., et al. “Mushrooms and immunity”. Autoimmune 117 (2021): 102576.
  8. Taek Joon Yoon., et al. “The effects of β-glucans on cancer metastasis”. Anti-Cancer Agents in Medicinal Chemistry 5 (2013): 699-708.
  9. Sabrin H Albeituni and Jun Yan. “The effects of β-glucans on dendritic cells and implications for cancer therapy”. Anti-Cancer Agents in Medicinal Chemistry 5 (2013): 689-698.
  10. Gorshenin DS., et al. “The use of chitosan and its derivatives in immunotherapy of malignant neoplasms”. Immunology5 (2020): 470-478.

Citation

Citation: AV Troitsky., et al. “Experimental Assessment of the Oncoprotective Properties of Low-Molecular Chitosan and its Effects on Cytostatic and Radiation Myelosuppression”.Acta Scientific Medical Sciences 8.8 (2024): 177-181.

Copyright

Copyright: © 2024 AV Troitsky., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US